

PATIENT DETAILS

Patient name:

DOB:

Phone:

Address:

Medicare:

Clinical trial / ID no.:

EXAMINATION

- PET with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis)**
 Plus Extremity (eg. Melanoma, Sarcoma, Myeloma, PUO, Vasculitis/Arteritis, Rheumatological or where limb involvement suspected)
- PET with localised diagnostic CT (please tick region/s)**
 Head Neck Chest Abdo Pelvis Extremity
- PET with Non-Diagnostic CT (attenuation correction)**

CLINICAL NOTES

PSMA

PSA:
Gleason score/ISUP grade group:

- Contrast Allergy
 Renal Impairment
 Surgery / Biopsy
 Radiation Therapy
 Chemotherapy
 Prior Imaging (when and where)

INDICATIONS

MBS ELIGIBLE ITEMS

- Solitary Pulmonary Nodule (61523)
 Non-Small Cell Lung cancer (61529)
Breast
 Staging (locally advanced) (61524)
 Suspected metastatic or recurrent (61525)

Brain Tumour

- Residual or Recurrent Malignant Tumour (61538)

Refractory Epilepsy (61559)

Melanoma (61553)

Ovarian Carcinoma (61565)

Cervix Carcinoma

- Primary Staging (61571)
 Restaging (61575)

Colorectal Carcinoma (61541)

Oesophageal/GOJ (staging) (61577)

Metastatic SCC Cervical Nodes

- Unknown Primary (61610)

Head & Neck

- Staging (61598)
 Restaging (61604)

Hodgkins or NHL

- Initial staging (61620)
 First line therapy response (61622)
 Restaging (61628)
 Second line therapy response (61632)

Sarcoma (excluding GIST)

- Staging (61640)
 Restaging/Residual/Recurrent (61646)

Diagnosis of Alzheimer's (61560)

PSMA

- Prostate staging (61563)
 Prostate recurrence (61564)

MBS INELIGIBLE ITEMS

- Other FDG PET
 FES
 FET
 Amyloid
 NaF
 Y90 SIRT
 Lu177 PSMA
 Ra223 Xofigo
 Other

MBS ineligible items will incur out of pocket fee. MBS items must be specialist referred.

REFERRING PRACTITIONER

Name:

Provider number:

Follow up appointment:

Send copy to:

Signature:

Date:

PET SPECIALISTS

Dr Dalveer Singh
 Dr Kevin Lee
 Dr Phillip Law

| | | |
|---------------------------------------|--------------|---|
| LUNG | | |
| Solitary Pulmonary Nodule | 61523 | Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed. |
| NSCLC | 61529 | Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned. |
| BRAIN | | |
| Brain | 61538 | FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. |
| Epilepsy | 61559 | FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery. |
| Alzheimer's | 61560 | FDG PET brain for diagnosis of Alzheimer's disease if clinical evaluation (by or in consultation with a specialist) is equivocal. Not repeatable within 12 months and not more than 3 per lifetime. |
| GASTROINTESTINAL | | |
| Colorectal | 61541 | Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy. |
| Oesophageal/GOJ | 61577 | Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy. |
| GYNAECOLOGY | | |
| Ovarian | 61565 | Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. |
| Uterine Cervix | 61571 | Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. |
| Uterine Cervix | 61575 | Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. |
| HEAD & NECK | | |
| Head & Neck | 61598 | Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer. |
| Head & Neck | 61604 | Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy. |
| MELANOMA | | |
| Melanoma | 61553 | Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy. |
| SCC | | |
| Metastatic SCC unknown primary | 61610 | Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes. |
| LYMPHOMA | | |
| Lymphoma | 61620 | Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma. |
| Lymphoma | 61622 | Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma. |
| Lymphoma | 61628 | Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma. |
| Lymphoma | 61632 | Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma. |
| SARCOMA | | |
| Bone or Soft Tissue Sarcoma | 61640 | Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. |
| Sarcoma | 61646 | Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. |
| BREAST | | |
| PET Breast | 61524 | Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.). |
| PET Breast | 61525 | Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.). |
| PSMA | | |
| Prostate Staging | 61563 | Whole Body PSMA PET for initial staging of intermediate to high risk prostate adenocarcinoma for previously untreated patient, considered for locoregional therapy with curative intent. Once per lifetime. |
| Prostate Recurrence | 61564 | Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma of patient who has undergone prior locoregional therapy and considered suitable for further locoregional therapy to determine appropriate further therapy. Twice per lifetime. |

ANNERLEY

Shop 7, 310 Ipswich Rd, Annerley QLD 4103
p: (07) 3357 0388 | f: (07) 3357 0380

NORTH LAKES PET-CT

9 McLennan Crt, North Lakes QLD 4509
p: (07) 3448 8840 | f: (07) 3880 6118

EMAIL

petbrisbane@qscan.com.au

All images are digitally archived for ten years and can be accessed by your doctor online anytime.
Your doctor has recommended you attend Qscan Radiology Clinics. You may choose another provider but please discuss this with your doctor first.

Trusted Analysis | Excellence | Compassionate Care

**ELECTRONIC REFERRALS
ARE ALSO AVAILABLE**



qscan.com.au